- hypersensitivity to carbamazepine or chemically similar medicinal products (eg, tricyclic antidepressants) or to any other component of the drug;
- atrioventricular block;
- the presence in the anamnesis of episodes of suppression of bone marrow hematopoiesis;
- hepatic porphyria;
- application in combination with MAO inhibitors (structural similarity with tricyclic antidepressants).
In those cases when during treatment a low level of white blood cells or platelets is noted, the patient’s condition and the parameters of the developed clinical blood test should be carefully monitored. If signs of significant bone marrow depression are detected, Tegretol should be withdrawn.
Tegretol should be immediately withdrawn if signs and symptoms, presumably indicative of the development of severe dermatological reactions, are noted.
Caution should be exercised when using Tegretol in patients with mixed forms of epileptic seizures, including absences (typical or atypical), due to possible increased seizures. If this happens, Tegretol should be canceled.
Patients who have a history of heart disease (including decompensated chronic heart failure), liver (including liver failure), kidney (including renal failure), adverse hematologic reactions to other drugs, or the withdrawal of previous treatment with Tegretol, should be prescribed only after a careful analysis of the relationship between the expected effect of treatment and the possible risk of therapy, and with careful and regular monitoring.